Dr Reddy's Gets DCGI Nod for Zytorvi, a New Immunotherapy for Esophageal Cancer
India's drug regulator has cleared Zytorvi as a first-line treatment for advanced esophageal squamous cell carcinoma, the most common form of the disease in the country.

India's drug regulator has approved a new immunotherapy for advanced esophageal cancer. Dr Reddy's Laboratories said on Wednesday, October 21, that the Drugs Controller General of India (DCGI) has cleared Zytorvi (toripalimab) for patients with advanced esophageal squamous cell carcinoma, or ESCC.
The approval covers use alongside two chemotherapy drugs, cisplatin and paclitaxel. It is meant as the first treatment for adults whose cancer cannot be removed by surgery, has returned, or has spread to other parts of the body.
This matters because ESCC makes up roughly 80 per cent of esophageal cancer cases in India, according to the company. So a new first-line option reaches a large share of patients with this diagnosis.
Zytorvi is an immunotherapy. It is a monoclonal antibody that targets a protein called PD-1 on immune cells. By blocking PD-1 from linking up with PD-L1 and PD-L2, it helps the body's T-cells keep working against cancer cells.
The company points to a Phase 3 trial called JUPITER-06 as the basis for approval. According to the company's release, adding toripalimab to chemotherapy cut the risk of the disease getting worse or of death by 42 per cent, compared with chemotherapy alone. In the final survival analysis, patients on the combination lived a median of 17.7 months, against 12.9 months for those on chemotherapy only.
This is the second use of Zytorvi cleared in India. It was already approved for nasopharyngeal carcinoma, a cancer that begins in the upper part of the throat behind the nose. Dr Reddy's holds rights to sell toripalimab in 21 countries under a 2023 deal with China's Junshi Biosciences.
The release did not say when the drug will reach hospitals or what it will cost. Patients should talk to their oncologist about whether this treatment suits them. Read the original report here.